Skip to main content
Uni-Bio Science Group Limited logo

Uni-Bio Science Group Limited — Investor Relations & Filings

Ticker · 690 HKEX Manufacturing
Open in API
Filings indexed 1,066 across all filing types
Latest filing 2014-06-30 Annual Report
Country HK Hong Kong
Listing HKEX 690

About Uni-Bio Science Group Limited

http://www.uni-bioscience.com

Uni-Bio Science Group Limited is an innovative biopharmaceutical enterprise specializing in the R&D, manufacturing, and sales of biological and chemical pharmaceutical products. The company's core strategy centers on regenerative medicine, focusing on therapeutic areas such as endocrinology, dermatology, and ophthalmology. Key research pipelines address bone and muscle regeneration (including osteoporosis), skin and tissue repair (burns, chronic wounds, and medical aesthetics), and ocular regeneration (corneal damage and macular degeneration). Unique technological platforms include the ECO-KSFA® micro-protein manufacturing system for high-stability biologics and smart hydrogel technology for advanced tissue engineering and targeted delivery solutions.

Recent filings

Filing Released Lang Actions
ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED 31 MARCH 2014
Annual Report Classification · 95% confidence The document is titled 'ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED 31 MARCH 2014' and contains detailed consolidated financial statements including profit or loss, comprehensive income, and statement of financial position for the full fiscal year ended 31 March 2014. It includes notes on accounting policies, application of new accounting standards, and detailed financial data. The length is substantial (15,000 characters) and the content is the full audited consolidated results, not merely an announcement or a summary. This matches the characteristics of an Annual Report (10-K equivalent) rather than a short earnings release or announcement. Therefore, the document is classified as an Annual Report (10-K). FY 2014
2014-06-30 English
VOLUNTARY ANNOUNCEMENT - rhPTH 1-34 PHASE III CLINICAL TRIAL RESULTS
Regulatory Filings Classification · 90% confidence The document is a voluntary announcement by Uni-Bio Science Group Limited regarding the results of a Phase III clinical trial for their drug Uni-PTH. It contains detailed clinical trial data, safety information, and future plans for regulatory submission to the Chinese Food and Drug Administration (CFDA). The document is not a financial report, earnings release, or regulatory filing related to financial performance. It is an announcement of clinical trial results, which is a type of operational update rather than a financial or governance report. Given the nature of the content and the absence of financial statements or management discussion of financial results, this document best fits the category of a Regulatory Filing (RNS) as a general announcement that does not fit other specific categories.
2014-06-30 English
DATE OF BOARD MEETING
Report Publication Announcement Classification · 95% confidence The document is a short announcement from Uni-Bio Science Group Limited stating the date of a board meeting to approve and publish the annual financial results for the year ended 31 March 2014. It does not contain the actual financial results or detailed report but merely announces the upcoming board meeting and the intention to approve and publish the annual results. The document length is only 1561 characters, which is quite short and fits the pattern of an announcement rather than a full report. According to the 'MENU VS MEAL' rule, this is an announcement about the timing of a report publication, not the report itself. Therefore, the appropriate classification is Report Publication Announcement (RPA).
2014-06-18 English
Next Day Disclosure Return
Share Issue/Capital Change Classification · 95% confidence The document is a Next Day Disclosure Return for a listed issuer, Uni-Bio Science Group Limited, reporting changes in issued share capital and share buybacks. It includes detailed information on share issues and repurchases pursuant to specific listing rules of the Hong Kong Stock Exchange. The content focuses on capital changes and share repurchase disclosures rather than financial results, management commentary, or regulatory certifications. The document length is 6298 characters, which is sufficient to contain substantive data. This matches the description of a Share Issue/Capital Change filing, which covers announcements regarding new share issues, stock splits, or other capital changes.
2014-06-06 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2014
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 31 May 2014, submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorised share capital, issued share capital, share options, warrants, convertibles, and other share-related transactions. The content focuses on changes in the company's capital structure and share issuance activities during the month. There are no financial statements, earnings data, management discussion, or audit information. The document is a regulatory filing reporting monthly share capital movements, typical for compliance with exchange rules. It is not an annual or interim report, earnings release, or management report. Given the detailed nature of share capital changes, it fits best under the category of Share Issue/Capital Change (SHA). The document length is substantial (14,799 characters), indicating it is the report itself, not just an announcement of a report publication.
2014-06-04 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 95% confidence The document is a Next Day Disclosure Return for a listed issuer, Uni-Bio Science Group Limited, reporting changes in issued share capital and share buybacks. It includes detailed information on share issues and repurchases pursuant to specific listing rules of the Hong Kong Stock Exchange. The content focuses on capital changes and share repurchase activities, with no financial statements or earnings data. This matches the description of a Transaction in Own Shares (POS) filing, which covers company buybacks or sales of its own shares. The document length is over 6000 characters and contains detailed data, not just an announcement or certification, so it is not RPA or RNS. Therefore, the correct classification is POS with high confidence.
2014-05-23 English

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.